Followers | 50 |
Posts | 12166 |
Boards Moderated | 0 |
Alias Born | 06/15/2014 |
Wednesday, October 16, 2024 10:42:29 AM
In my taxable account, AMRN is my only non-dividend paying stock (after retiring purchased divvy stocks for income), and in my retirement accounts AMRN is among several spec stocks although I have been gradually shifting those accounts into divvy stocks since next year I have to start taking RMDs. Looking at the portfolio, on the whole the stocks have done quite well, even those other spec stocks. BUT AMRN is amazing, in that even crappy stocks bounce every 6 or 12 months, but here with Amarin we are just mired in quicksand. If by some fluke this damn thing could pop up to $4 or $5, my financial situation would be set. Just hard to understand how this can just sit, sit, sit, slide, sit, sit, slide..... ad infinitum. I suppose, like I have said before, the market looks at future prospects and it does not comprehend how income can come in sufficiently fast enough to stem the losses. We need some new developments but damn if I can see any on the horizon. Anyway sorry for the rant.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
FEATURED Zefiro Methane Corp. Subsidiary Awarded Slate of Government of Ohio-Funded Environmental Remediation Projects • Jan 15, 2025 7:33 AM
FEATURED Mawson Finland Begins 2025 Drill Program, Mobilizing Multiple Drill Rigs at Rajapalot • Jan 15, 2025 7:18 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM
UAV Corp (OTC: UMAV) Engages Legal Counsel to Initiate Uplisting Process with Ultimate Goal of NASDAQ Listing • UMAV • Jan 15, 2025 8:30 AM
HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer • HLYK • Jan 15, 2025 8:00 AM
GreetEat Corporation Announces Ticker Symbol Change to GEAT on OTC Markets • GEAT • Jan 14, 2025 9:40 AM